4 ms·

Oxford one is also going to be easier to manufacture given that it is based on existing technology. Many countries e.g. Australia are licensing the formula so

Oxford one is also going to be easier to manufacture given that it is based on existing technology. Many countries e.g. Australia are licensing the formula so this is an important aspect.

singingfish 6y ago
the mRNA style viruses will probably decrease in cost exponentially the same way that DNA sequencing and computer technology have dropped in price.
- starfallg 6y ago
  However, mRNA vaccines require low temperature storage and are in general harder to handle. This translates to additional cost in production, throughout the logistics chain and delivery.
  - singingfish 6y ago
    I think it's likely that they'll need to be distributed frozen, but there's a lot that can be done researching preservatives. The the moderna vaccine is higher temperature than the pfveizer one for this reason.
  - twic 6y ago
    Pfizer are also working on a lyophilised, aka freeze-dried, version of their vaccine, which would not need to be stored at -80 C. This is from July [1], not sure if there is any more news: > But we also hope to have, as we always do in life cycle management, a new lyophilized formulated vaccine by -- within maybe a year after initial delivery such as fourth quarter 2021 and the lyophilized formulation could be stored in refrigerator. [1] https://s21.q4cdn.com/317678438/files/PFE-USQ_Transcript_2020-07-01.pdf https://s21.q4cdn.com/317678438/files/PFE-USQ_Transcript_202...
Nitramp 6y ago
I read the opposite - producing mRNA fragments at scale is supposedly cheaper than producing the inactivated vector viruses with the correct payload.
- intpx 6y ago
  no real idea, but my guess is that its likely true that mRNA fragment production is cheaper, but inactivated vector manufacturing is already scaled up and out globally and mRNA is not-- existing labs around the world can maybe be more easily equipped to scale up production?

Oxford one is also going to be easier to manufacture given that it is based on existing technology. Many countries e.g. Australia are licensing the formula so this is an important aspect.

singingfish 6y ago

the mRNA style viruses will probably decrease in cost exponentially the same way that DNA sequencing and computer technology have dropped in price.

starfallg 6y ago
However, mRNA vaccines require low temperature storage and are in general harder to handle. This translates to additional cost in production, throughout the logistics chain and delivery.
- singingfish 6y ago
  I think it's likely that they'll need to be distributed frozen, but there's a lot that can be done researching preservatives. The the moderna vaccine is higher temperature than the pfveizer one for this reason.
- twic 6y ago
  Pfizer are also working on a lyophilised, aka freeze-dried, version of their vaccine, which would not need to be stored at -80 C. This is from July [1], not sure if there is any more news: > But we also hope to have, as we always do in life cycle management, a new lyophilized formulated vaccine by -- within maybe a year after initial delivery such as fourth quarter 2021 and the lyophilized formulation could be stored in refrigerator. [1] https://s21.q4cdn.com/317678438/files/PFE-USQ_Transcript_2020-07-01.pdf https://s21.q4cdn.com/317678438/files/PFE-USQ_Transcript_202...

Nitramp 6y ago

I read the opposite - producing mRNA fragments at scale is supposedly cheaper than producing the inactivated vector viruses with the correct payload.

intpx 6y ago
no real idea, but my guess is that its likely true that mRNA fragment production is cheaper, but inactivated vector manufacturing is already scaled up and out globally and mRNA is not-- existing labs around the world can maybe be more easily equipped to scale up production?